Evidence map›Paper›PMID 18340411›Full record

Trial reportNeurocritical care2008

Combined intravenous and intraarterial revascularization therapy using MRI perfusion/diffusion mismatch selection for acute ischemic stroke at 3-6 h after symptom onset.

Moon-Ku Han, Sung Hyun Kim, Sang-Bae Ko, Nam-Jong Paik, O-Ki Kwon, Yong-Seok Lee, Chang-Wan Oh, Jae Hyoung Kim, Seong-Ho Park, Hee-Joon Bae

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Neurocritical care, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Moon-Ku HanDepartment of Neurology, Seoul National University Bundang Hospital, 300, Gumi-Dong, Bundang-Gu, Seongnam 463-707, Korea.
Sung Hyun Kim
Sang-Bae Ko
Nam-Jong Paik
O-Ki Kwon
Yong-Seok Lee
Chang-Wan Oh
Jae Hyoung Kim
Seong-Ho Park
Hee-Joon Bae

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeIntravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) has demonstrated favorable clinical outcomes in a 3-6 h window in patients selected with perfusion/diffusion mismatch. However, the advantages of combined IV and intraarterial (IA) thrombolysis after 3 h of stroke onset are unexplored.

methodsAcute ischemic stroke patients with persistent occlusion of intracranial large arteries were screened prospectively for thrombolysis by evaluating perfusion/diffusion mismatch on MRI. The IV rt-PA was initiated within 3-6 h, and additional urokinase (UK) was then administered via the IA route after angiography.

resultsFour patients had middle cerebral artery occlusion and one patient had an internal carotid artery occlusion. The median time from the symptom onset to the initiation of IV therapy and to the initiation of IA treatment was 215 +/- 30 min and 292 +/- 41 min, respectively. The median National Institutes of Health Stroke Scale (NIHSS) scores were as follows: initial, 13; immediately after IA treatment, 8; at 24 h, 5; and at 7 days, 3. The Thrombolysis in Myocardial Infarction (TIMI) score after the completion of thrombolysis was 2-3. Four patients without intracerebral hemorrhage recovered completely or exhibited mild disability and one patient with hemorrhage also demonstrated a favorable outcome.

conclusionThis preliminary result suggests that if a significant perfusion/diffusion mismatch on MRI is identified, a sequential combination thrombolysis of IV rt-PA and IA UK is potentially beneficial in moderate to severe acute ischemic stroke patients who are treated within 3-6 h after symptom onset.

Indexed as

Diffusion Magnetic Resonance ImagingAcute DiseaseAdultAgedBrain IschemiaCerebral AngiographyCerebral RevascularizationDrug Therapy, CombinationFeasibility StudiesFemaleFibrinolytic AgentsHumansInjections, Intra-ArterialInjections, IntravenousMaleMiddle AgedFibrinolytic AgentsTissue Plasminogen ActivatorUrokinase-Type Plasminogen Activator

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.